Stemline Therapeutics (Stemline Therapeutics) Equity-to-Asset : 0.87 (As of Mar. 2020)

View and export this data going back to 2013. Start your Free Trial

What is Stemline Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Stemline Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2020 was $147.65 Mil. Stemline Therapeutics's Total Assets for the quarter that ended in Mar. 2020 was $170.61 Mil. Therefore, Stemline Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2020 was 0.87.

The historical rank and industry rank for Stemline Therapeutics's Equity-to-Asset or its related term are showing as below:

STML's Equity-to-Asset is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.66
* Ranked among companies with meaningful Equity-to-Asset only.

Stemline Therapeutics Equity-to-Asset Historical Data

The historical data trend for Stemline Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stemline Therapeutics Equity-to-Asset Chart

Stemline Therapeutics Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Equity-to-Asset

Get a 7-Day Free Trial

0.90

0.85

0.70

0.67

0.88

Stemline Therapeutics Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
Equity-to-Asset	Get a 7-Day Free Trial															0.80	0.79	0.89	0.88	0.87

Competitive Comparison of Stemline Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Stemline Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stemline Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stemline Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Stemline Therapeutics's Equity-to-Asset falls into.

Stemline Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Stemline Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2019 is calculated as

Equity to Asset (A: Dec. 2019 )	=	Total Stockholders Equity	/	Total Assets
	=	163.616	/	186.979
	=	0.88

Stemline Therapeutics's Equity to Asset Ratio for the quarter that ended in Mar. 2020 is calculated as

Equity to Asset (Q: Mar. 2020 )	=	Total Stockholders Equity	/	Total Assets
	=	147.647	/	170.611
	=	0.87

Stemline Therapeutics (NAS:STML) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Stemline Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Stemline Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Stemline Therapeutics (Stemline Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stemline Therapeutics Inc (NAS:STML) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

750 Lexington Avenue, 11th Floor, New York, NY, USA, 10022

Website

http://www.stemline.com

Stemline Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is involved in the business of discovering, acquiring and developing and commercializing therapeutics for oncology indications of unmet medical need. Its pipeline product candidates include felezonexor (SL-801, an XPO1 inhibitor), SL-1001 (a RET kinase inhibitor), SL-901 (a kinase inhibitor) and SL-701 (an immunotherapy). The company is also involved in advancing its clinical stage programs, expanding and strengthening its intellectual property portfolio, identifying and acquiring additional product and technology rights.

Executives

Darren S Cline	director	35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Kenneth J Zuerblis	director	20 KINGSBRIDGE RD, PISCATAWAY NJ 08854
Daniel Hume	director	3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK NY 10019
Kenneth Hoberman	officer: Chief Operating Officer	750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024
Ron Bentsur	director	750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Alan S Forman	director	55 WHITNEY AVENUE, 5TH FLOOR, NEW HAVEN CT 06511
Eric Dobmeier	director	C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
J Kevin Buchi	director	41 MOORES ROAD, FRAZER PA 19355
Eric K Rowinsky	officer: Chief Medical Officer	IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014